Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 73 of 131 for:    Pancreatic Cancer | ( Map: South Korea )

Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03695757
Recruitment Status : Recruiting
First Posted : October 4, 2018
Last Update Posted : May 31, 2019
Sponsor:
Information provided by (Responsible Party):
Dong-Ho Nahm, Ajou University School of Medicine

Brief Summary:
The purpose of this prospective pilot clinical study is to evaluate the safety and immunostimulatory effect of intramuscularly administrations of autologous total IgG (autologous total IgG therapy) in healthy subjects and patients with advanced solid tumor (non-small cell lung cancer, stomach cancer, colon cancer, ovarian cancer, breast cancer, pancreatic cancer, biliary cancer, melanoma, renal cell carcinoma etc.). In addition, antitumor effect of intramuscularly administrations of autologous total IgG in patients with advanced solid tumor will be also evaluated.

Condition or disease Intervention/treatment Phase
Immunotherapy Biological: Part A) Healthy subjects Biological: Part B) Advanced solid tumor Phase 1 Phase 2

Detailed Description:

After providing informed consent, study participants will be assessed for study eligibility at the screening visit. At screening visit (week -4), venous blood (320~400 mL) will be sampled using a double blood bag containing anticoagulant. Autologous plasma will be separated from the venous blood by centrifugation. During the 4 weeks of screening period, autologous total IgG (purity ≥97%) will be aseptically purified from the autologous plasma by chromatography using Protein A. Participants will receive the 8 intramuscular injections of autologous total IgG, twice a week for 4 weeks from baseline (week 0).

The investigators will evaluate the safety and immunostimulatory effect of intervention of this study by analyzing side effects, serum concentrations of immunological parameters (immunoglobulin, cytokine, etc.), and lymphocyte fraction by flow cytometry analysis of peripheral blood mononuclear cells.

[Part A) Autologous total IgG therapy in healthy subjects] The duration of this clinical study in healthy subjects is 16 weeks from the screening visit. A 4-week screening period will be followed by a 4-week intervention period and an 8-week follow-up period.

[Part B) Autologous total IgG therapy in patients with advanced solid tumor] The duration of this clinical study in patients with advanced solid tumor is 12 weeks from the screening visit. A 4-week screening period will be followed by a 4-week intervention period and a 4-week follow-up period(1 cycle).

If the patients agree to participate in additional long-term repeated study interventions at the end of 1st cycle of visit, patients will receive repeated study interventions in same the schedule up to week 44 (maximum 4 cycles). At the end of each cycle, antitumor effect will be evaluated by serum tumor marker concentrations, anatomical imaging, and Response Evaluation Criteria in solid tumors (RECIST ver. 1.1).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: Intramuscularly administrations of autologous total IgG in healthy subjects and patients with advanced solid tumor
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Immunostimulatory Effect of Intramuscular Administration of Autologous Total IgG in Human for Development of a New Immunotherapy
Actual Study Start Date : November 6, 2018
Estimated Primary Completion Date : May 31, 2021
Estimated Study Completion Date : May 31, 2021

Arm Intervention/treatment
Experimental: Part A) Healthy subjects
Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
Biological: Part A) Healthy subjects
Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
Other Name: Intramuscular injections of autologous total IgG

Experimental: Part B) Advanced solid tumor
Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
Biological: Part B) Advanced solid tumor
Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
Other Name: Intramuscular injections of autologous total IgG




Primary Outcome Measures :
  1. Number of participants with severe adverse events (AEs), serious adverse events (SAEs), treatment-related AEs, deaths, or discontinuation of study intervention due to AEs in healthy subjects [ Time Frame: From baseline to week 12 ]
  2. Number of participants with severe adverse events (AEs), serious adverse events (SAEs), treatment-related AEs, deaths, or discontinuation of study intervention due to AEs in patients with advanced solid tumor [ Time Frame: From baseline to week 8 and through study completion, an average of 3 year ]

Secondary Outcome Measures :
  1. Number of participants with abnormal serum chemistry results and blood test results due to clinical study in healthy subjects [ Time Frame: From baseline to week 12 ]
  2. Serum concentrations of immunological parameters (immunoglobulin, cytokine, etc.) in healthy subjects [ Time Frame: From baseline to week 12 ]
  3. Lymphocyte fraction by flow cytometry analysis of peripheral blood mononuclear cells in healthy subjects [ Time Frame: From baseline to week 12 ]
  4. Levels of cytokines secreted from peripheral blood cells in healthy subjects [ Time Frame: From baseline to week 12 ]
  5. Quality of life (5-level EuroQoL Group's 5-dimension; EQ-5D-5L) in healthy subjects [ Time Frame: From baseline to week 12 ]
    The 5-level EuroQoL Group's 5-dimension (EQ-5D-5L) consists of 2 parts: the descriptive system and the EQ visual analogue scale (VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels of perceived problems: no problems, slight problems, moderate problems, severe problems, and unable to/extreme problems. In addition, the EQ-5D-5L include an EQ-VAS where the endpoints are labeled on a scale from 0 (worst imaginable health) to 100 (best imaginable health).

  6. Subjective index of pain and fatigue (Visual Analogue Scale; VAS, Numeral Rating Scale; NRS) in healthy subjects [ Time Frame: From baseline to week 12 ]
    The 100-mm Visual Analogue Scale (VAS) ranges from 0 (absent) to 10 (worst imaginable). The 11-point Numerical Rating Scale (NRS) ranges from 0 (absent) to 10 (worst imaginable).

  7. Number of participants with abnormal serum chemistry results and blood test results due to clinical study in patients with advanced solid tumor [ Time Frame: From baseline to week 8 and through study completion, an average of 3 year ]
  8. Serum concentrations of immunological parameters (immunoglobulin, cytokine, etc.) in patients with advanced solid tumor [ Time Frame: From baseline to week 8 and through study completion, an average of 3 year ]
  9. Lymphocyte fraction by flow cytometry analysis of peripheral blood mononuclear cells in patients with advanced solid tumor [ Time Frame: From baseline to week 8 and through study completion, an average of 3 year ]
  10. Levels of cytokines secreted from peripheral blood cells in patients with advanced solid tumor [ Time Frame: From baseline to week 8 and through study completion, an average of 3 year ]
  11. Objective response rate (ORR) in patients with advanced solid tumor [ Time Frame: From baseline to week 8 and through study completion, an average of 3 year ]
  12. Disease control rate (DCR) in patients with advanced solid tumor [ Time Frame: From baseline to week 8 and through study completion, an average of 3 year ]
  13. Duration of response (DOR) in patients with advanced solid tumor [ Time Frame: From baseline to week 8 and through study completion, an average of 3 year ]
  14. Progression-free survival (PFS) in patients with advanced solid tumor [ Time Frame: From baseline to week 8 and through study completion, an average of 3 year ]
  15. Overall survival (OS) in patients with advanced solid tumor [ Time Frame: From baseline to week 8 and through study completion, an average of 3 year ]
  16. The tumor marker concentrations in patients with advanced solid tumor [ Time Frame: From baseline to week 8 and through study completion, an average of 3 year ]
  17. Quality of life (5-level EuroQoL Group's 5-dimension; EQ-5D-5L) in patients with advanced solid tumor [ Time Frame: From baseline to week 8 and through study completion, an average of 3 year ]
    The 5-level EuroQoL Group's 5-dimension (EQ-5D-5L) consists of 2 parts: the descriptive system and the EQ visual analogue scale (VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels of perceived problems: no problems, slight problems, moderate problems, severe problems, and unable to/extreme problems. In addition, the EQ-5D-5L include an EQ-VAS where the endpoints are labeled on a scale from 0 (worst imaginable health) to 100 (best imaginable health).

  18. Subjective index of pain and fatigue (Visual Analogue Scale; VAS, Numeral Rating Scale; NRS) in patients with advanced solid tumor [ Time Frame: From baseline to week 8 and through study completion, an average of 3 year ]
    The 100-mm Visual Analogue Scale (VAS) ranges from 0 (absent) to 10 (worst imaginable). The 11-point Numerical Rating Scale (NRS) ranges from 0 (absent) to 10 (worst imaginable).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female, 19 years or older
  2. Meeting the criteria for autologous blood donation 1) Body weight ≥32 kg (satisfying body weight limitation for planned sampling of 320 mL of venous blood volume) 2) Hemoglobin: ≥ 11g/dL
  3. Provide signed informed consent
  4. [Only for patients with advanced solid tumor] Patients with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2 at the time of study enrollment.
  5. [Only for patients with advanced solid tumor] Patients with a life expectancy longer than 3 months and metastatic (stage Ⅳ) advanced solid tumor (non-small cell lung cancer, stomach cancer, colon cancer, ovarian cancer, breast cancer, pancreatic cancer, cholangiocarcinoma, malignant melanoma, renal cell carcinoma, etc.)
  6. [Only for patients with advanced solid tumor] One or more target lesions must be present as confirmed by anatomical imaging (X-ray, CT sacn, MRI, etc.)

Exclusion Criteria:

  1. Subjects under the age of 19 year, or unable to agree on their own (emergency patients, patients with mental disability, patients with limited capacity to consent due to stroke or delirium caused by diabetes), or severe disease whose expected survival duration is less than 3 months
  2. Pregnancy or planned pregnancy within 1 year
  3. Subjects who participated on another investigational device or drug studies within 4 weeks prior to screening visit
  4. Medical history of alcohol or drug abuse within 2 years of the screening visit
  5. Subjects is a member of the investigational team
  6. Unable to comply with all clinic visits and study-related procedures
  7. Planned or anticipated major surgical procedure within 4 weeks prior to baseline visit
  8. [Only for patients with advanced solid tumor] A well-treated patients in combination with surgery and radiotherapy
  9. [Only for patients with advanced solid tumor] Uncontrolled infections (bacterial, viral, fungal infection)
  10. [Only for patients with advanced solid tumor] Has known active brain metastases(except for subjects with adequate treated and neurological asymptomatic at least 2 weeks, subjects without neurological symptoms without treatment for brain metastases, also subjects must be either off corticosteroid for corticosteroid therapy, or who have received stable doses of prednisone less than 10mg daily or who have received reduced doses may be enrolled
  11. [Only for patients with advanced solid tumor] In patients receiving chemotherapy, immunotherapy, radiotherapy, or treatment with hormone replacement therapy at the time of screening visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03695757


Contacts
Layout table for location contacts
Contact: Dong-Ho Nahm 82312195150 dhnahm@gmail.com
Contact: Ji-Sun Kang 82312198256 kjs21250@naver.com

Locations
Layout table for location information
Korea, Republic of
Ajou university hosiptal Recruiting
Suwon, Gyeong-gi Do, Korea, Republic of, 16499
Contact: Dong-Ho Nahm, M.D.    82312195150    dhnahm@gmail.com   
Sponsors and Collaborators
Ajou University School of Medicine
Investigators
Layout table for investigator information
Principal Investigator: Dong-Ho Nahm Ajou University School of Medicine

Layout table for additonal information
Responsible Party: Dong-Ho Nahm, Professor, Ajou University School of Medicine
ClinicalTrials.gov Identifier: NCT03695757     History of Changes
Other Study ID Numbers: AJIRB-MED-THE-18-236
First Posted: October 4, 2018    Key Record Dates
Last Update Posted: May 31, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Dong-Ho Nahm, Ajou University School of Medicine:
Immunoglobulin G
Treatment
Immunostimulatory effect
Tumor
Solid tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Immunoglobulin G
Immunologic Factors
Physiological Effects of Drugs